<b>BTG plc Given Overweight Rating at JPMorgan Chase & Co. (BTG) November 17th, 2015</b>
BTG plc (LON:BTG)‘s stock had its “overweight” rating restated by equities researchers at JPMorgan Chase & Co. in a research report issued on Tuesday, Analyst Ratings Net reports. They presently have a GBX 900 ($13.69) price target on the stock. JPMorgan Chase & Co.’s target price would indicate a potential upside of 55.17% from the stock’s previous close.
BTG has been the subject of several other research reports. FinnCap reissued a “sell” rating and set a GBX 562 ($8.55) price target on shares of BTG plc in a report on Thursday, August 6th. Stifel Nicolaus increased their target price on shares of BTG plc from GBX 540 ($8.21) to GBX 550 ($8.37) and gave the company a “sell” rating in a report on Thursday, August 6th. Jefferies Group dropped their price objective on shares of BTG plc from GBX 950 ($14.45) to GBX 850 ($12.93) and set a “buy” rating for the company in a research note on Thursday, September 17th. Panmure Gordon restated a “buy” rating and set a GBX 1,035 ($15.74) target price on shares of BTG plc in a research report on Tuesday, October 6th. Finally, Deutsche Bank reiterated a “buy” rating and issued a GBX 940 ($14.30) price target on shares of BTG plc in a report on Wednesday, October 7th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of GBX 778.70 ($11.85).
BTG plc (LON:BTG) opened at 580.00 on Tuesday. The stock’s market cap is GBX 2.22 billion. BTG plc has a 1-year low of GBX 504.00 and a 1-year high of GBX 835.87. The firm’s 50 day moving average price is GBX 569.17 and its 200-day moving average price is GBX 644.00.
BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (LON:BTG) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from accredited assets). The Company’s Interventional Medicine section offers a portfolio of interventional medication products that were created to improve the treatment of complex emphysema, liver tumors, acute blood clots and varicose veins. The Company’s Specialty Pharmaceuticals segment offers a portfolio of antidote products that relieve toxicity and treat rare illnesses. The Organization ‘s Licensing section receives royalties concerning the sales of products which are subject to license agreements and intellectual property between the Company and various partners. The Company’s subsidiary companies comprise BTG International (Holdings) Ltd, Provensis Ltd, BTG International Ltd and BTG Employee Share Schemes Ltd, amongst others.
"Basic and diluted adjusted earnings per share (excluding acquisition adjustments and reorganisation costs) was previously stated as 18.7p and 18.4p respectively on an underlying earnings of £71.4m. A mathematical error in calculating underlying earnings added back instead of eliminating from the calculation the £7.5m post-tax impact of the fair value changes on contingent consideration, described in Note 6 of the Interim Financial Statements. As a consequence, underlying earnings has now been amended to £56.4m,"
It was even part of the financial summary:
Adjusted earnings per share (excluding acquisition adjustments and reorganisation costs) were 35% higher at 18.7p (H1 14/15: 13.9p)
Even so, this sell off does seem a bit overdone. It was down nearly 25% yesterday from the close prior to the update. Two large trades of around a million shares each snuck in at 537.5p before the close yesterday so I guess someone is seeing this downturn as a buying opportunity?
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.